RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Esperion Therapeutics Stock

Esperion Therapeutics ROA 2024

Esperion Therapeutics ROA

-1.02

Ticker

ESPR

ISIN

US29664W1053

WKN

A1W1SJ

In 2024, Esperion Therapeutics's return on assets (ROA) was -1.02, a 7.86% increase from the -0.94 ROA in the previous year.

Esperion Therapeutics Aktienanalyse

What does Esperion Therapeutics do?

Esperion Therapeutics Inc is a company specialized in researching and developing innovative therapies for the treatment of heart diseases. It was founded in 2008 and is headquartered in Ann Arbor, Michigan. History: The founding of Esperion is closely connected with the history of another pharmaceutical company, Pfizer. In 2003, Pfizer introduced the drug Lipitor, used for treating high cholesterol levels. Lipitor quickly became one of the most successful medications worldwide, generating billions in revenue over the following years. Esperion Therapeutics Inc was founded to develop an alternative to Lipitor that would be better tolerated and potentially more effective. The company relied on the expertise of Dr. Roger Newton, the former research director at Pfizer involved in the development of Lipitor. Business model: Esperion's business model is based on acquiring patents for new compounds and then investigating these compounds in clinical trials. If a compound shows promise, Esperion can apply for approval from the US Food and Drug Administration (FDA) and bring the medication to market. The company has also formed a partnership with Daiichi-Sankyo to market its products in Japan and other Asian countries. Segments: Esperion focuses on developing therapies for the treatment of hyperlipidemia, or high cholesterol levels. This means the company develops medications that lower LDL cholesterol levels and reduce the risk of heart and vascular diseases. One promising compound from Esperion is ETC-1002. This medication is currently being tested in clinical trials and has the potential to be an effective alternative to conventional statins, as it does not have the same undesired effects. Other products: Esperion also has a division called Esperion Diabetes Solutions, which focuses on developing therapies for the treatment of type 2 diabetes. However, this is still in the development stage. Additionally, the company has another compound in clinical development called Bempedoic Acid. This medication acts at the cellular level to inhibit cholesterol synthesis in the body. Conclusion: Esperion Therapeutics is a company specializing in the development of innovative therapies for the treatment of heart diseases. The company focuses on lowering LDL cholesterol levels and reducing the risk of heart and vascular diseases. Esperion's promising product is ETC-1002, which has the potential to be an effective alternative to conventional statins. Through its partnership with Daiichi-Sankyo, the company also has access to Asian markets. Esperion Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Esperion Therapeutics's Return on Assets (ROA)

Esperion Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Esperion Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Esperion Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Esperion Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Esperion Therapeutics stock

What is the Return on Assets (ROA) of Esperion Therapeutics this year?

The Return on Assets (ROA) of Esperion Therapeutics is -1.02 undefined this year.

What was the ROA of Esperion Therapeutics compared to the previous year?

The ROA of Esperion Therapeutics has increased by 7.86% compared to the previous year.

What consequences do high ROA have for investors of Esperion Therapeutics?

A high ROA is advantageous for investors of Esperion Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Esperion Therapeutics?

A low ROA can be unfavorable for investors of Esperion Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Esperion Therapeutics affect the company?

An increase in ROA of Esperion Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Esperion Therapeutics impact the company?

A reduction in the ROA of Esperion Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Esperion Therapeutics?

Some factors that can influence the ROA of Esperion Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Esperion Therapeutics important for investors?

The ROA of Esperion Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Esperion Therapeutics take to improve ROA?

To improve ROA, Esperion Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Esperion Therapeutics pay?

Over the past 12 months, Esperion Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Esperion Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Esperion Therapeutics?

The current dividend yield of Esperion Therapeutics is .

When does Esperion Therapeutics pay dividends?

Esperion Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Esperion Therapeutics?

Esperion Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Esperion Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Esperion Therapeutics located?

Esperion Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Esperion Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Esperion Therapeutics from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Esperion Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Esperion Therapeutics in the year 2023?

In the year 2023, Esperion Therapeutics distributed 0 USD as dividends.

In which currency does Esperion Therapeutics pay out the dividend?

The dividends of Esperion Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Esperion Therapeutics

Our stock analysis for Esperion Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Esperion Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.